about
The diversity of the bacterial communities associated with the azooxanthellate hexacoral Cirrhipathes lutkeni.The bacterial community of the lithistid sponge Discodermia spp. as determined by cultivation and culture-independent methods.Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity.In vitro activity of commercial probiotic Lactobacillus strains against uropathogenic Escherichia coli.Rate of establishing the gut microbiota in infancy has consequences for future health.Mining marine shellfish wastes for bioactive molecules: chitin and chitosan--Part A: extraction methods.Mining marine shellfish wastes for bioactive molecules: chitin and chitosan--Part B: applications.A duplex qPCR for the simultaneous detection of Escherichia coli O157:H7 and Listeria monocytogenes using LNA probes.Isolation & identification of bacteria for the treatment of brown crab (Cancer pagurus) waste to produce chitinous material.Use of batch culture and a two-stage continuous culture system to study the effect of supplemental alpha-lactalbumin and glycomacropeptide on mixed populations of human gut bacteria.A two-stage continuous culture system to study the effect of supplemental alpha-lactalbumin and glycomacropeptide on mixed cultures of human gut bacteria challenged with enteropathogenic Escherichia coli and Salmonella serotype Typhimurium.The effects of alpha-lactalbumin and glycomacropeptide on the association of CaCo-2 cells by enteropathogenic Escherichia coli, Salmonella typhimurium and Shigella flexneri.Some insights into the derivation and early uses of the word 'probiotic'.Semiquantitative polymerase chain reaction enzyme immunoassay for the diagnosis of pertussisrRNA probes used to quantify the effects of glycomacropeptide and alpha-lactalbumin supplementation on the predominant groups of intestinal bacteria of infant rhesus monkeys challenged with enteropathogenic Escherichia coliEffects of bovine alpha-lactalbumin and casein glycomacropeptide-enriched infant formulae on faecal microbiota in healthy term infants
P50
Q33307518-B41FEC2A-5CDA-41A3-ACA7-F72E70ABF765Q34242944-148D1800-D3EB-46ED-BD25-D8B41BF5CC64Q35069368-9ADFBEF1-AA84-42EC-BD05-B508B1F324B1Q35664689-3850C466-5C92-4A61-B1AD-931DFF102921Q35826984-434FDA77-90E6-49E0-B7C5-9FA1428C4B71Q37102332-477CEA96-C39B-419D-8298-95A7AB1FDAF7Q37102345-DD0DD3E2-0792-443D-B585-B198CDBCDBD0Q41078378-17A1ED31-C12D-429F-8BBC-C009699364E1Q41490692-6F5B09CD-B4E9-440F-BB00-D6E7B61E19B2Q43285579-B8AD0B3D-0EDB-45F8-901D-E7CFAEF28CA9Q44478536-399D8AE9-0F23-48A7-93FC-55A391E63281Q50081120-E09DCDE6-318D-478F-A75D-3CCE579409D4Q55037832-57B27ED5-A337-4A01-91EF-358340C859ECQ73235450-399235D6-A58B-47EB-8E3C-F00F6F32DE2FQ73911280-7D527EA6-4DE3-4286-B203-E714EB5A8529Q79387128-7BD2B87D-3B42-48A8-A2B8-2B66BD61132B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wolfram M Brück
@ast
Wolfram M Brück
@en
Wolfram M Brück
@es
Wolfram M Brück
@nl
Wolfram M Brück
@sl
type
label
Wolfram M Brück
@ast
Wolfram M Brück
@en
Wolfram M Brück
@es
Wolfram M Brück
@nl
Wolfram M Brück
@sl
prefLabel
Wolfram M Brück
@ast
Wolfram M Brück
@en
Wolfram M Brück
@es
Wolfram M Brück
@nl
Wolfram M Brück
@sl
P106
P1153
14519211000
P31
P496
0000-0002-4516-5146